Literature DB >> 9608348

Medication take-home doses and contingency management.

J M Schmitz1, H M Rhoades, R Elk, D Creson, I Hussein, J Grabowski.   

Abstract

Two studies examined contingent take-home medication doses during treatment of opiate or cocaine dependence. In the first study, methadone maintenance patients were randomly assigned to one of two 8-week baseline take-home (TH) conditions differing in frequency of clinic visits per week. This was followed by a 12-week contingency management (CM) procedure in which frequent THs resulted from drug-free urines. Participants receiving more frequent THs during baseline had lower illicit drug use during the first 6 weeks of CM. In the second study, fluoxetine (0-, 20-, 40-mg) TH doses were similarly contingent in treatment of cocaine dependence. The 40-mg group used less cocaine during contingency than did other groups. The combination of fluoxetine and environmental contingencies may produce benefit where neither alone is sufficient.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9608348     DOI: 10.1037//1064-1297.6.2.162

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  14 in total

1.  Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms.

Authors:  Alison Oliveto; James Poling; Michael J Mancino; D Keith Williams; Jeff Thostenson; Rhonda Pruzinsky; Kishorchandra Gonsai; Mehmet Sofuoglu; Gerardo Gonzalez; Shanti Tripathi; Thomas R Kosten
Journal:  Addiction       Date:  2011-10-10       Impact factor: 6.526

2.  Contingency management and levodopa-carbidopa for cocaine treatment: a comparison of three behavioral targets.

Authors:  Joy M Schmitz; Jan A Lindsay; Angela L Stotts; Charles E Green; F Gerard Moeller
Journal:  Exp Clin Psychopharmacol       Date:  2010-06       Impact factor: 3.157

3.  A randomized controlled trial of fluoxetine in the treatment of cocaine dependence among methadone-maintained patients.

Authors:  Erin L Winstanley; George E Bigelow; Kenneth Silverman; Rolley E Johnson; Eric C Strain
Journal:  J Subst Abuse Treat       Date:  2011-01-26

4.  Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: two double-blind, randomized, clinical trials.

Authors:  Marc E Mooney; Joy M Schmitz; F Gerard Moeller; John Grabowski
Journal:  Drug Alcohol Depend       Date:  2006-11-28       Impact factor: 4.492

5.  Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms.

Authors:  Michael J Mancino; Janette McGaugh; Mohit P Chopra; Joseph B Guise; Christopher Cargile; D Keith Williams; Jeff Thostenson; Thomas R Kosten; Nichole Sanders; Alison Oliveto
Journal:  J Clin Psychopharmacol       Date:  2014-04       Impact factor: 3.153

6.  Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform.

Authors:  Joy M Schmitz; Marc E Mooney; F Gerard Moeller; Angela L Stotts; Charles Green; John Grabowski
Journal:  Drug Alcohol Depend       Date:  2007-12-27       Impact factor: 4.492

7.  Duration effects in contingency management treatment of methamphetamine disorders.

Authors:  John M Roll; Joy Chudzynski; Jennifer M Cameron; Donelle N Howell; Sterling McPherson
Journal:  Addict Behav       Date:  2013-04-03       Impact factor: 3.913

8.  High-dose naltrexone therapy for cocaine-alcohol dependence.

Authors:  Joy M Schmitz; Jan A Lindsay; Charles E Green; David V Herin; Angela L Stotts; F Gerard Moeller
Journal:  Am J Addict       Date:  2009 Sep-Oct

9.  Community opioid treatment perspectives on contingency management: perceived feasibility, effectiveness, and transportability of social and financial incentives.

Authors:  Bryan Hartzler; Carl Rabun
Journal:  J Subst Abuse Treat       Date:  2013-03-16

10.  A meta-analysis of retention in methadone maintenance by dose and dosing strategy.

Authors:  Yan-Ping Bao; Zhi-Min Liu; David H Epstein; Cun Du; Jie Shi; Lin Lu
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.